Clinical Trial Update: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant endocrine therapy trial in hormone receptor-positive, HER2-negative, node-negative breast cancer completed. Results posted 2022-10-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Breast Cancer

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Breast Cancer, Invasive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-10-18